Novartis Ag

William Leonard Wishart

Pamposh Ganju

Jonathan Hall

Maria Wanda Hemmings

Gabriele Dorn

Josef Prassler

Ingo Klagge

Adrian Walmsley

Marta Cortes-Cros

Adrian Robert Walmsley

The present invention provides a binding molecule which is capable of binding to the rat, cynomolgus monkey and human LINGO polypeptide, and a polynucleotide encoding the binding molecule. The invention also provides an expression vector comprising the polynucleotide, an expression system comprising a polynucleotide capable of producing a binding molecule, as well as an isolated host cell comprising the expression system for producing the binding molecule. The invention also provides for compositions comprising the LINGO binding molecules and the use of binding molecule compositions as a pharmaceutical, especially in the treatment to promote axonal regeneration/plasticity. The invention further provides for a method of treatment of diseases associated with axonal degeneration and demyelination.

LINGO binding molecules and pharmaceutical use thereof

The present invention relates to methods to treat neurological disorders comprising intrathecal injection of an effective amount of a double-stranded (ds) RNA into a subject in need, wherein the dsRNA inhibits the expression of a target gene and to pharmaceutical compositions useful for such treatment.

Treatment of neurological disorders by dsRNA administration

Growing community of inventors

Allschwil, Switzerland

William Leonard Wishart